BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 27306529)

  • 1. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.
    Nankivell BJ; Borrows RJ; Fung CL; O'Connell PJ; Chapman JR; Allen RD
    Transplantation; 2004 Aug; 78(4):557-65. PubMed ID: 15446315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
    Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
    Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
    Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
    Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
    Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
    Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity.
    Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR
    Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy.
    Snanoudj R; Royal V; Elie C; Rabant M; Girardin C; Morelon E; Kreis H; Fournet JC; Noël LH; Legendre C
    Am J Transplant; 2011 Dec; 11(12):2635-46. PubMed ID: 21883915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis.
    Azarfar A; Ravanshad Y; Mehrad-Majd H; Esmaeeli M; Aval SB; Emadzadeh M; Salehi M; Moradi A; Golsorkhi M; Khazaei MR
    Saudi J Kidney Dis Transpl; 2018; 29(6):1376-1385. PubMed ID: 30588970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus.
    Fuchs U; Klein S; Zittermann A; Ensminger SM; Schulz U; Gummert JF
    Ann Transplant; 2014 Jun; 19():300-4. PubMed ID: 24953848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
    Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity.
    Bentata Y
    Artif Organs; 2020 Feb; 44(2):140-152. PubMed ID: 31386765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
    Roodnat JI; Hilbrands LB; Hené RJ; de Sévaux RG; Smak Gregoor PJ; Kal-van Gestel JA; Konijn C; van Zuilen A; van Gelder T; Hoitsma AJ; Weimar W
    Transplantation; 2014 Jul; 98(1):47-53. PubMed ID: 24521775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.